December 2017 Issue of MMM
Drugmakers are proud of the patient service programs they've developed. Yet there remains a disconnect in the way information is communicated to HCPs.
The need to simplify access to treatment while finding new ways to keep patients engaged in their health and adherent is an undeniably growing trend.
Technology like this could expand further to form better collaborations between pharma, payers and organized providers.
The most promising products in pharma's pipeline will compete in a landscape that increasingly rewards big risks and places an emphasis on novel mechanisms. That ...
The first year of the Trump administration was kind to pharma, but it might not be so fortunate in 2018.
Innovation-minded executives share their thoughts and predictions for the year ahead.
Whatever REDUCE-IT ultimately reveals (results from the completed study are expected in Q2 or Q3 2018), Salyer maintains Amarin has "a great story to tell, ...
Optum vet Miller replaces Jessica Boden.
Ty Curran, previously CEO of the sister agencies, will serve as chairman in 2018.
Two years after the first biosimilar approval in the U.S., biosimilars have yet to match sales forecasts. What is their path forward?
How should marketers position this new type of cancer therapy?
Although it's a long way from the president's desk, the Tax Cut and Jobs Act of 2017 contains plenty of good news for the life ...
Only 2.6% of board members in Standard & Poor's 1,500 firms have marketing experience.
Our understanding of how cancer develops and thrives has grown.
Rapp's Nic Climer examines the tension in tragedy and darkness.
At Work With
The CEO and founder of Antidote talks about what inspired him to start the company, which recently received funding from Merck.
It turns out the real goal is going after Washington's favorite whipping boy — high drug prices.